Publications dans lesquelles il/elle collabore avec Pau Montesinos (13)

2023

  1. Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia

    Blood Advances, Vol. 7, Núm. 1, pp. 167-173

2021

  1. Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia

    Leukemia, Vol. 35, Núm. 8, pp. 2358-2370

2020

  1. Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project

    Haematologica, Vol. Online ahead of print

2018

  1. Focal adhesion genes refine the intermediate-risk cytogenetic classification of acute myeloid leukemia

    Cancers, Vol. 10, Núm. 11

2016

  1. Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia

    Leukemia Research, Vol. 40, pp. 1-9

2011

  1. Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens

    Blood, Vol. 117, Núm. 6, pp. 1799-1805

  2. Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy

    Haematologica, Vol. 96, Núm. 10, pp. 1470-1477

2010

  1. Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy

    Haematologica, Vol. 95, Núm. 3, pp. 424-431

  2. Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group

    Blood, Vol. 116, Núm. 25, pp. 5650-5659

2009

  1. Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis

    Haematologica, Vol. 94, Núm. 9, pp. 1242-1249

  2. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all- trans retinoic acid and anthracycline chemotherapy: Characteristics, outcome, and prognostic factors

    Blood, Vol. 113, Núm. 4, pp. 775-783

2008

  1. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin

    Blood, Vol. 111, Núm. 7, pp. 3395-3402

  2. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: Long-term outcome of the LPA 99 multicenter study by the PETHEMA Group

    Blood, Vol. 112, Núm. 8, pp. 3130-3134